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Summary
Background Glucose management is challenging in patients who require nutritional support in hospital. We aimed to 
assess whether fully closed-loop insulin delivery would improve glycaemic control compared with conventional 
subcutaneous insulin therapy in inpatients receiving enteral or parenteral nutrition or both.
Methods We did a two-centre (UK and Switzerland), open-label, randomised controlled trial in adult inpatients 
receiving enteral or parenteral nutrition (or both) who required subcutaneous insulin therapy. Patients recruited from 
non-critical care surgical and medical wards were randomly assigned (1:1) using a computer-generated minimisation 
schedule (stratified by type of nutritional support [parenteral nutrition on or off] and pre-study total daily insulin dose 
[<50 or ≥50 units]) to receive fully closed-loop insulin delivery with faster-acting insulin aspart (closed-loop group) or 
conventional subcutaneous insulin therapy (control group) given in accordance with local clinical practice. Continuous 
glucose monitoring in the control group was masked to patients, ward staff, and investigators. Patients were followed 
up for a maximum of 15 days or until hospital discharge. The primary endpoint was the proportion of time that 
sensor glucose concentration was in target range (5·6–10·0 mmol/L), assessed in the intention-to-treat population. 
This trial is registered with ClinicalTrials.gov, number NCT01774565.
Findings Between Feb 8, 2018, and Sept 21, 2018, 90 patients were assessed for eligibility, of whom 43 were enrolled and 
randomly assigned to the closed-loop group (n=21) or the control group (n=22). The proportion of time that sensor 
glucose was in the target range was 68·4% [SD 15·5] in the closed-loop group and 36·4% [26·6] in the control group 
(difference 32·0 percentage points [95% CI 18·5–45·5; p<0·0001]). One serious adverse event occurred in each group 
(one cardiac arrest in the control group and one episode of acute respiratory failure in the closed-loop group), both of 
which were unrelated to study interventions. There were no adverse events related to study interventions in either 
group. No episodes of severe hypoglycaemia or hyperglycaemia with ketonaemia occurred in either study group. 
Interpretation Closed-loop insulin delivery is an effective treatment option to improve glycaemic control in patients 
receiving nutritional support in hospital.
Funding Diabetes UK, Swiss National Science Foundation, National Institute for Health Research Cambridge 
Biomedical Research Centre, Wellcome Trust, and European Foundation for the Study of Diabetes.
Copyright © The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY 4·0 license.
Introduction
Nutritional support with enteral or parenteral nutrition is 
an important component of medical care.1 Hyperglycaemia 
is common in patients receiving nutritional support in 
non-critical care, occurring in up to half of those receiving 
parenteral nutrition and in a third of those receiving 
enteral nutrition.2,3 The carbohydrate content of nutritional 
support can exacerbate other causes of hyper glycaemia 
in hospital inpatients, such as metabolic responses to 
acute illness and medications that alter insulin sensitivity 
(eg, glucocorticoids).
Hyperglycaemia occurring in inpatients receiving 
parenteral or enteral nutrition, with or without a history of 
diabetes, is associated with increased morbidity and 
mortality.4–6 Observational studies4,5,7–9 have shown that the 
risks of infection, cardiac complications, acute renal 
failure, respiratory failure, and mortality increase as mean 
blood glucose increases in patients receiving parenteral 
nutrition.
Clinical practice guidelines for inpatient glucose 
management in non-critical care have been proposed,10 
but implementation in patients receiving enteral 
or parenteral nutrition is particularly challenging. 
Unanticipated dislodgement of feeding tubes, temporary 
discontinuation of nutrition because of nausea or for 
administration of medication or diagnostic testing, and 
cycling of nutritional support with oral intake all 
necessitate a high level of vigilance among health-care 
professionals, including frequent blood glucose 
monitoring, regular adjustment of insulin doses, 
and pre-emptive administration of carbohydrates to 
minimise the risk of hypoglycaemia. Glucose 
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management in this population is associated with a 
substantially increased workload for ward staff, and fear 
of hypoglycaemia often leads to suboptimal glycaemic 
control.
Closed-loop systems, which automatically deliver 
insulin in a glucose-responsive manner, might provide a 
solution to glucose management for hospital inpatients 
requiring nutritional support. Closed-loop systems 
combine real-time glucose measurements from a 
continuous glucose monitoring (CGM) device with 
a control algorithm that directs insulin delivery via an 
insulin pump. Evidence that closed-loop technology 
improves glycaemic control in inpatients with hyper-
glycaemia is increasing, but systematic investigations in 
the most challenging circum stances, such as during 
parenteral or enteral nutrition, have not been done.8,11
Here we report the results of a two-centre, randomised, 
open-label trial of fully closed-loop insulin delivery in 
a diverse cohort of inpatients receiving enteral or 
parenteral nutrition (or both) in non-critical medical and 
surgical care. We hypothesised that closed-loop insulin 
delivery would be safe and improve glycaemic control 
without increasing the risk of hypoglycaemia.
Methods
Study design and participants
In this two-centre, open-label, randomised controlled 
trial, participants were recruited from non-critical care 
Research in context
Evidence before this study
We searched PubMed for articles published from Jan 1, 2000, 
up to Dec 1, 2018, using the search terms (“closed-loop” OR 
“artificial pancreas”) AND (“type 2 diabetes” OR “inpatient 
hyperglycaemia” OR “stress hyperglycaemia” OR [“hospital” 
AND “hyperglycaemia” AND “nutrition”]) to identify previous 
studies on the management of inpatient hyperglycaemia in 
non-critical care. Two previous inpatient studies have 
investigated the use of closed-loop insulin delivery in patients 
with type 2 diabetes in non-critical care. The larger of these 
randomised controlled trials was done in 136 adult patients 
with type 2 diabetes and compared conventional subcutaneous 
insulin therapy with closed-loop insulin delivery in non-critical 
care. Over a period of up to 15 days, the proportion of time spent 
in the target glucose range (5·6–10·0 mmol/L) and mean blood 
glucose concentrations were significantly improved with 
closed-loop therapy, without an increase in hypoglycaemia. 
Our search did not yield any previous studies that used 
closed-loop insulin delivery in hospital inpatients receiving 
nutritional support. Alternative strategies to improve glucose 
management in patients receiving nutritional support include 
the use of variable-rate intravenous insulin infusion; however, 
this support is associated with increased staff workload. In a 
non-randomised prospective study of 605 inpatients receiving 
parenteral nutrition, intravenous insulin (infusion therapy or 
added to parenteral nutrition bag) was associated with a greater 
risk of hypoglycaemia compared with subcutaneous or no 
insulin therapy. Overall glucose control was not reported. 
A retrospective study showed suboptimal glucose control using 
intravenous insulin infusion to treat parenteral nutrition-related 
hyperglycaemia in the non-intensive care setting. Subcutaneous 
insulin pump therapy titrated every 4 h has shown benefits in 
glycaemic variability over multiple daily insulin injections 
titrated every 4 h in a randomised trial involving 
102 post-surgical patients receiving parenteral nutrition in 
hospital, but it requires substantial input from health-care 
providers and does not provide glucose concentration feedback. 
Studies have shown that insulin availability is affected by the 
composition of the parenteral nutrition infusion containers 
(adsorption with plastic-containing surfaces is much greater 
than with glass). The presence of a multivitamin and trace 
element additive is associated with much greater insulin 
availability than parenteral nutrition solutions without additive. 
The GLUCOSE-in-PN randomised trial showed no difference in 
mean glucose concentration achieved with continuously 
infused insulin in parenteral nutrition compared with 
subcutaneously administered long-acting insulin in non-
critically ill surgical patients receiving parenteral nutrition.
Added value of this study
Our study is, to our knowledge, the first to assess fully 
automated closed-loop insulin delivery without meal bolusing 
in adults in non-critical care receiving enteral or parenteral 
nutrition (or both). We showed that an increased proportion of 
time was spent in the target glucose range and mean glucose 
was reduced with fully closed-loop insulin delivery compared 
with standard insulin therapy, without an increase in the time 
spent in hypoglycaemia or the total daily insulin dose. 
This study shows that fully closed-loop insulin delivery can 
potentially provide health-care professionals with an effective 
and safe clinical tool to manage hyperglycaemia in patients 
receiving parenteral or enteral nutritional support in hospital.
Implications of all the available evidence
Clinical guidelines for inpatient glucose management in 
non-critical care have been published. However, data from 
inpatient audits and studies show that implementation is 
challenging, particularly in patients receiving enteral or 
parenteral nutrition. Unanticipated dislodgement of feeding 
tubes, temporary discontinuation of nutrition, and cycling 
of nutritional support with oral intake necessitate high levels 
of vigilance among health-care professionals, including 
frequent blood glucose monitoring and regular adjustment of 
insulin doses. Glucose management in this population is 
associated with increased workload for ward staff, and fear of 
hypoglycaemia often leads to suboptimal glycaemic control. 
Further studies are needed to assess the potential of 
closed-loop insulin delivery to improve clinical outcomes, 
including morbidity and mortality, in this setting.
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wards at Addenbrooke’s Hospital (Cambridge, UK) and 
Bern University Hospital (Bern, Switzerland). Included 
patients were aged 18 years or older, had a prescription 
for enteral or parenteral nutrition, and had inpatient 
hyperglycaemia requiring subcutaneous insulin therapy 
during hospital admission. Exclusion criteria were type 1 
diabetes, pregnancy or breastfeeding, and any physical 
or psychological disease or the use of one or more 
medication likely to interfere with the conduct of the 
trial or interpretation of the results. Full inclusion and 
exclusion criteria are available in the appendix. 
Inpatients were identified through hospital electronic 
records. Written informed consent was obtained from 
participants who had capacity to consent, or from 
relatives of participants who did not have capacity to 
consent (UK participants only) before the start of study-
related procedures. The study protocol was approved by 
the local research ethics committees (East of England 
Central Cambridge Ethics Committee, UK; and Ethics 
Committee Bern, Switzerland) and regulatory authorities 
(Medicines and Healthcare products Regulatory Agency, 
UK; and Swissmedic, Switzerland). The safety of the 
trial was overseen by an independent data and safety 
monitoring board. The trial was done in accordance with 
the principles of the Declaration of Helsinki. The full 
trial protocol is available in the appendix. 
Randomisation and masking
Eligible participants were randomly assigned (1:1) to 
either fully closed-loop insulin delivery with faster-acting 
insulin aspart (closed-loop group) or conventional 
subcutaneous insulin therapy (control group; multiple 
different types of insulin regimens were used by 
participants and participants might have used several 
different insulin regimens during their time in the study 
as per standard clinical practice). Randomisation was 
done with the minimisation method, generated by Minim 
randomisation software,12 which is a biased coin approach 
with a probability of 0·7–0·8 of allocation to the best 
fitting treatment. This method aims to minimise 
imbalance between groups. The allocation algorithm 
takes into consideration the characteristics of previously 
allocated participants to determine the best fitting treat-
ment group. Randomisation was stratified by the type of 
nutritional support (parenteral nutrition on or off) and 
pre-study total daily insulin dose (<50 or ≥50 units) to 
balance the two study groups. This was an open-label 
study, but the CGM receiver in the control group was 
modified to mask the sensor glucose measurements to 
the participant, investigators, and ward staff.
Procedures
Participant bodyweight, height, and total daily insulin 
dose were recorded after enrolment. The study did not alter 
or specify the nutrition regimens prescribed by the local 
clinical team, and participants did not have their usual 
activity restricted.
In the closed-loop group, participants’ usual insulin 
therapy and sulfonylurea medication, if prescribed, was 
discontinued on the day of closed-loop initialisation. All 
other medications were continued. A subcutaneous 
cannula was inserted by the investigator in the abdomen 
or arm for delivery of faster-acting insulin aspart 
(Fiasp, Novo Nordisk, Bagsværd, Denmark) by a study 
pump (Dana R Diabecare, Seoul, South Korea). 
A subcutaneous real-time CGM sensor (Freestyle 
Navigator II, Abbott Diabetes Care, Alameda, CA, USA) 
was inserted in the upper arm or abdomen by 
the investigator and calibrated in accordance with the 
manufacturer’s instructions. When sensor glucose data 
became available, fully closed-loop glycaemic control was 
started by the investigator. A low glucose sensor alarm on 
the CGM receiver was initialised at a threshold of 
3·5 mmol/L.
The FlorenceD2W-T2 automated closed-loop system 
consisted of a model predictive control algorithm 
(version 0.3.70) residing on a control algorithm device 
(Dell Latitude 10 tablet, Dell, Bracknell, UK) linked by a 
Universal Serial Bus cable to the CGM receiver (FreeStyle 
Navigator II; appendix). The tablet device communicated 
with the study pump via a Bluetooth wireless commun-
ication protocol. The control algorithm was initialised 
with the participant’s weight and pre-study total daily 
insulin dose.
No prandial insulin boluses were delivered and the 
control algorithm did not receive data on timing or 
carbohydrate content of meals or enteral and parenteral 
feeds. Every 12 min the control algorithm calculated the 
required insulin infusion rate on the basis of sensor 
glucose measurements. The study pump was then 
instructed by wireless communication to adjust insulin 
delivery. The control algorithm adapted itself to a particular 
patient by updating model parameters and refining the 
patient’s insulin requirements. The algorithm aimed 
to achieve glucose concentrations between 5·8 and 
7·2 mmol/L and adjusted the actual target concentration 
depending on the accuracy of the model-based glucose 
predictions and prevailing glucose concentrations. Safety 
rules limited maximum insulin infusion and suspended 
insulin delivery at a sensor glucose measurement of 
4·2 mmol/L or less, or when sensor glucose was rapidly 
decreasing. In the event of sensor failure or loss of sensor 
availability, the CGM receiver sounded an audible alarm 
that alerted the general ward or the research team. 
If sensor glucose data continued to be unavailable for 
30 min, the study pump insulin infusion rate reverted to 
the preprogrammed basal rate. For longer interruptions of 
sensor glucose data, the control algorithm could use 
capillary glucose measurements to direct insulin delivery.
Point-of-care capillary glucose measurements (StatStrip 
Glucose Hospital Meter System, Nova Biomedical, 
Runcorn, UK; or Accu-Chek Inform II, Roche Diagnostics, 
Basel, Switzerland) were done by ward nursing staff in 
accordance with to local clinical practice.
See Online for appendix
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At the end of the closed-loop period, participants 
completed a brief questionnaire providing feedback on 
their satisfaction with glycaemic control while on closed-
loop therapy, acceptance of wearing study devices, and 
whether they would recommend closed-loop therapy to 
others. Participants’ usual insulin therapy and sulfonylurea 
medication were restarted at the end of closed-loop use as 
appropriate.
In the conventional insulin therapy group, participants’ 
insulin therapy at randomisation and other anti-
hyperglycaemic therapies were continued throughout the 
study period. A CGM sensor (Freestyle Navigator II) was 
inserted by the investigator on the first day of the study 
and calibrated in accordance with the manufacturer’s 
instructions.
Point-of-care capillary glucose measurements (StatStrip 
Glucose Hospital Meter System or Accu-Chek Inform II) 
were done by ward nursing staff. Each participant’s 
glycaemic control was managed by the participant’s 
clinical team in accordance with local clinical practice. 
The clinical team were allowed to modify and adjust 
participants’ insulin and other antihyperglycaemic 
therapies and initiate additional point-of-care capillary 
glucose measurements as appropriate. Both centres have 
an inpatient diabetes service and patients in the control 
group referred to the diabetes team had capillary glucose 
reviewed every 1–2 days depending on patient complexity, 
with insulin doses adjusted as required. Patients not 
referred to the inpatient diabetes team had capillary 
glucose monitored and insulin dose adjusted by the 
clinical team. 
Closed-loop insulin delivery was continued for up to 
15 days or until hospital discharge. To reflect local clinical 
practice, in the UK, closed-loop insulin delivery was 
stopped if nutritional support was stopped and the 
diabetes team deemed that subcutaneous insulin therapy 
was no longer required; data collection was stopped at 
this point in both closed-loop and control groups. In 
Switzerland, data collection continued in both closed-loop 
and control groups up to 15 days or until discharge.
Outcomes
The primary outcome was the proportion of time the 
sensor glucose measurement was in the target glucose 
range of 5·6–10·0 mmol/L during the study period. 
Secondary outcomes were the proportion of time that 
the sensor glucose measurement was either higher or 
lower than the target range; the proportion of time it was 
higher than 20·0 mmol/L, lower than 3·9 mmol/L, lower 
than 3·0 mmol/L, and lower than 2·8 mmol/L; the 
burden of hypoglycaemia, assessed by the area under 
the curve (AUC) less than 3·5 mmol/L and less than 
3·0 mmol/L; the mean sensor glucose measurement; 
and the total daily insulin dose.
Secondary outcome measures of glycaemic variability 
was assessed by the SD and the coefficient of variation in 
sensor glucose measurements using data collected from 
the whole study period. The between-day coefficient of 
variation in sensor glucose measurements was calculated 
from daily mean glucose measurements (midnight 
to midnight). Daytime (0800–0000 h) and overnight 
(0000–0800 h) results were calculated for a subset of 
prespecified exploratory outcomes (time in target range, 
time above target range, mean sensor glucose measure-
ment, the SD and the coefficient of variation in sensor 
glucose measurement, the between-days and between-
nights coefficient of variation in sensor glucose measure-
ments, and AUC less than 3·5 mmol/L, with the use of 
data from the respective periods) to limit multiple 
comparisons. The mean pre-meal and pre-bed capillary 
glucose measurements at each defined period were 
calculated per participant for the whole study period. 
Daily carbohydrate intake was calculated, and route of 
delivery recorded, per participant for the study period. 
Assessment of the experience of participants in the 
closed-loop group was collected at the end of the study 
period.
Safety endpoints were severe hypoglycaemia 
(<2·2 mmol/L) and clinically significant hypergly caemia 
(>20 mmol/L) with ketonaemia, as determined by point-of-
care capillary measurements, as well as device deficiencies, 
adverse events, and serious adverse events. Since the study 
was done in hospital inpatients, many of whom had a 
serious health condition or life-threatening illness at 
enrolment, only unanticipated adverse events and events 
relating to the study interventions were reported. 
Statistical analysis
This was an exploratory study in which we planned for up 
to 45 patients to be randomly assigned. Since previous 
inpatient closed-loop studies might not provide reliable 
information about the SD of the primary endpoint in 
patients receiving parenteral or enteral nutrition (or both), 
we applied no formal power calculation. The sample size 
corresponds to the sample size of a previous inpatient 
feasibility closed-loop randomised trial.8
We analysed efficacy and safety data by an intention to 
treat. We calculated outcomes with GStat software 
(version 2.3) and did statistical analyses with SPSS 
(version 25). An unpaired t test was used to compare 
normally distributed variables and the Mann-Whitney 
U test was used for highly skewed variables. We tabulated 
the numbers of events (a prespecified saftey outcome) 
that were related to a capillary glucose measurement of 
less than 3·5 mmol/L, less than 2·2 mmol/L, and more 
than 20 mmol/L in each trial group and we compared the 
proportion of participants with events in each group with 
Fisher’s exact test. We report values as mean (SD) or 
median (IQR), unless stated otherwise. We made no 
allowance for multiplicity. All p values are two-tailed, and 
p values of less than 0·05 were deemed to indicate 
statistical significance. 
This trial is registered with ClinicalTrials.gov, number 
NCT01774565.
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Role of the funding source
The funders of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. CKB, LB, and RH had full access 
to all the data in the study and take responsibility for 
the integrity of the data and the accuracy of the data 
analysis. All authors made the decision to submit for 
publication.
Results
From Feb 8, 2018, to Sept 21, 2018, 90 participants were 
considered for enrolment, of whom 43 were eligible and 
consented; 21 were randomly assigned to the closed-loop 
group and 22 to the control group (figure 1). Across both 
study groups, roughly 80% of CGM sensors were 
inserted in the upper arm and 20% were inserted in the 
abdomen. The study period was terminated before 
reaching predetermined study endpoints (15 days, 
hospital discharge, or no requirement for insulin 
therapy) in five patients in the closed-loop group and ten 
patients in the control group. The most common reason 
participants stopped the study prematurely was because 
of discomfort wearing study devices, usually due to the 
additional capillary glucose measurements required for 
sensor calibration (n=3 in the closed-loop group; n=7 in 
the control group); study stopping points are outlined in 
the appendix.
The baseline characteristics of the closed-loop group 
and control group were similar (table 1). The proportion 
of male patients was higher in Cambridge than in Bern 
(90% vs 55%), and participants in Cambridge were 
younger and had higher baseline HbA1c (appendix). The 
most common hyperglycaemia treatment at recruitment 
was basal-bolus insulin in 21 (49%) or basal insulin alone 
in ten (23%) participants (appendix). Gastro intestinal 
malignancy was the pre dominant reason for hospital 
admission (14 [33%] of 43 participants; appendix). The 
mean Charlson Comorbidity Index score was higher in 
the closed-loop group than in the control group 
(appendix). Total hospital stay was longer in the control 
group (median 32 days [IQR 25–47]) than in the closed-
loop group (18 days [14–26]; p=0·013); however, length of 
hospital stay from study enrolment to discharge was 
similar between groups (15 days [9–30] in the control 
group vs 10 days [6–19] in the closed-loop group; p=0·13).
The study duration, defined as the period from the 
first sensor reading until last sensor reading, was similar 
between groups (6·7 days [SD 4·0] in the closed-loop 
group and 6·7 days [4·3] in the control group; p=0·99; 
appendix) and included suspension of the study period 
in four patients in the closed-loop group and six patients 
in the control group due to intensive care transfer, 
surgery, or other procedures, which required transient 
removal of study devices. In Switzerland, all participants 
required insulin after nutritional support was stopped, so 
data collection continued in both closed-loop and control 
groups up to 15 days or until discharge. In the UK, four 
participants did not require insulin after nutritional 
support was stopped. Sensor glucose data were available 
for 97·4% (SD 3·8) of the study period (excluding 
47 excluded
 19 declined to participate
 10 imminent discharge
 10 ineligible
 8 unable to consent
90 patients approached to participate
43 randomly assigned
21 allocated to fully automated 
 closed-loop insulin delivery
 14 received enteral nutrition
 6 received parenteral nutrition
 1 received enteral and 
 parenteral nutrition
22 allocated to conventional
 subcutaneous insulin therapy
 13 received enteral nutrition
 7 received parenteral nutrition
 2 received enteral and 
 parenteral nutrition
21 included in intention-to-treat 
 analysis
17 completed survey
22 included in intention-to-treat 
 analysis
Figure 1: Trial profile
Closed-loop 
group (n=21)
Control group 
(n=22)
Sex
Women 7 (33%) 5 (23%)
Men 14 (67%) 17 (77%)
Age, years 66·2 (13·6) 69·1 (9·9)
BMI, kg/m² 27·0 (4·3) 29·3 (5·1)
HbA1c* 7·3% (1·6) 7·4% (1·8)
HbA1c, mmol/mol* 56 (17) 57 (19)
Type of diabetes
Type 2 10 (48%) 12 (54%)
Pancreatic 5 (24%) 2 (9%)
Type 2 and pancreatic 3 (14%) 7 (32%)
Type 2 and steroids 1 (5%) 0
Pancreatic and steroids 1 (5%) 1 (5%)
Feed induced 1 (5%) 0
Duration of diabetes, years† 11·1 (13·9) 7·1 (7·5)
Duration on insulin therapy, years 3·2 (9·0) 3·0 (5·9)
Total daily insulin, U/kg 0·6 (0·4) 0·6 (0·3)
Total daily insulin <50 units 15 (71%) 14 (64%)
Participants recruited in Cambridge 10 (48%) 11 (50%)
Participants recruited in Bern 11 (52%) 11 (50%)
Data are n (%) or mean (SD). *Data available for 17 participants in the closed-loop 
group and 19 participants in the control group. †Data available for 20 participants 
in the closed-loop group and 21 participants in the control group.
Table 1: Baseline characteristics
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suspension periods) in the closed-loop group and 91·8% 
(8·1) in the control group (p=0·007). Closed-loop therapy 
was operational for 99·2% (4·1) of the time when sensor 
glucose data were available.
Total daily carbohydrate intake and daily carbohydrate 
received via parenteral, enteral, and oral intake were 
similar between groups (appendix). About a third of 
participants received parenteral nutrition and two-thirds 
received enteral nutrition. Fewer than 10% received both 
parenteral and enteral nutrition during the study (figure 1).
The proportion of time sensor glucose concentration 
was in the target range (5·6–10·0 mmol/L; the primary 
outcome) was significantly higher in the closed-loop 
group (68·4% [SD 15·5]) than in the control group (36·4% 
[26·6]; difference 32·0 percentage points [95% CI 
18·5–45·5]; p<0·0001; table 2). Mean sensor glucose 
concentration was significantly lower in the closed-loop 
group (8·5 mmol/L [1·2]) than in the control group 
(11·4 mmol/L [3·4]; difference 2·9 mmol/L [1·3–4·5]; 
p=0·001; table 2). The proportion of time spent 
at concentrations higher than the target range 
(>10·0 mmol/L) was 32·6 percentage points lower 
(17·8–47·3; p<0·0001) in the closed-loop group than in 
the control group, but the time spent at less than the 
target range (<5·6 mmol/L) did not differ between groups 
(table 2). The proportion of time spent with concentrations 
less than 3·9 mmol/L, less than 3·0 mmol/L, and less 
than 2·8 mmol/L, and burden of hypoglycaemia (as 
measured by AUC less than 3·5 mmol/L), were low and 
similar between groups (table 2). Glycaemic control 
outcomes by site and by nutritional support regimen are 
shown in the appendix.
Total daily insulin delivery did not differ significantly 
between groups (table 2). Glycaemic variability during 
closed-loop therapy, as measured by SD of sensor glucose 
measurement, was significantly reduced compared with 
conventional insulin therapy (table 2). Pre-bed capillary 
glucose concentration did not differ significantly between 
groups, but pre-breakfast, pre-lunch, and pre-evening 
meal glucose concentrations were higher in the control 
group than in the closed-loop group (table 2). 24 h sensor 
glucose data and insulin delivery profiles are shown in 
figure 2.
The proportion of time that overnight (0000–0800 h) and 
daytime (0800–0000 h) sensor glucose concentration was 
in the target range was significantly higher in the closed-
loop group than in the control group (overnight difference 
30·1 percentage points [95% CI 15·3–44·8; p=0·0002]; 
daytime difference 32·1 percentage points [18·4–45·7; 
p<0·0001]; table 3). Mean sensor glucose was significantly 
lower in the closed-loop group than in the control group 
overnight and during daytime periods (table 3). SD of 
sensor glucose overnight and during daytime periods was 
significantly lower in the closed-loop group than in the 
control group (table 3). Overnight and daytime burden of 
hypoglycaemia, as measured by AUC less than 3·5 mmol/L, 
did not differ significantly between groups (table 3).
Closed-loop experience questionnaires were completed 
by 17 (81%) of 21 participants in the closed-loop 
group (three participants were unable to complete the 
questionnaire due to impaired cognition, and one 
participant self-discharged before receiving the question-
naire). Overall, 100% (17/17) of those who completed the 
questionnaire stated that their diabetes treatment in 
hospital during the study was as expected or better than 
expected and 100% reported that having their glycaemia 
controlled automatically by the closed-loop system was as 
expected or better than expected (appendix). All 
17 participants who completed the questionnaire would 
recommend the system to a friend or family if they were 
admitted to hospital.
Four hypoglycaemic episodes with capillary glucose 
concentration of less than 3·5 mmol/L, confirmed by 
point-of-care measurements, occurred in the closed-loop 
group (two participants), compared with nine episodes in 
the control group (five participants). These episodes were 
treated with oral or enteral carbohydrates in accordance 
with local guidelines by the ward staff, with intravenous 
Closed-loop group 
(n=21)
Control group 
(n=22)
p value
Proportion of time spent at glucose concentration
5·6–10·0 mmol/L* 68·4% (15·5) 36·4% (26·6) <0·0001 
>10·0 mmol/L 22·2% (15·7) 54·8% (29·7) <0·0001 
>20·0 mmol/L 0·3% (0·7) 6·2% (13·9) 0·06
<5·6 mmol/L 9·3% (6·3) 8·7% (10·3) 0·82
<3·9 mmol/L 0·5% (0·0–1·5) 0·5% (0·0–2·9) 0·74
<3·0 mmol/L 0·0% (0·0–0·2) 0·0% (0·0–0·8) 0·37
<2·8 mmol/L 0·0% (0·0–0·1) 0·0% (0·0–0·5) 0·31
Mean glucose concentration, mmol/L 8·5 (1·2) 11·4 (3·4) 0·001
SD of glucose concentration, mmol/L 2·3 (0·8) 3·4 (1·4) 0·003
Coefficient of variation of glucose 
concentration
26·7% (6·2) 29·7% (9·7) 0·24
Between-days coefficient of variation of sensor 
glucose
14·7% (6·1) 20·0% (11·7) 0·07
AUCDay <3·5 mmol/L (mmol/L × min) 1·7 (0·0–24·9) 3·6 (3·5–113·5) 0·58
AUCDay <3·0 mmol/L (mmol/L × min) 0·0 (0·0–4·4) 0·0 (0·0–20·1) 0·39
Total daily insulin dose (units) 53·9 (26·9–82·6) 40·3 (28·8–52·7) 0·47
Capillary glucose concentrations†
Pre-breakfast, mmol/L (0500–0800 h) 8·4 (1·6) 11·1 (4·5) 0·014
Pre-lunch, mmol/L (1100–1300 h) 8·7 (2·1) 13·6 (4·8) 0·0003
Pre-evening meal, mmol/L (1600–1900 h) 7·9 (1·2) 11·3 (4·4) 0·002
Pre-bed, mmol/L (2100–0000 h) 9·1 (1·7) 10·7 (4·9) 0·17
Number of events with capillary glucose 
<3·5 mmol/L
4 9 ..
Number of participants with capillary glucose 
<3·5 mmol/L
2 (10%) 5 (23%) 0·25
Number of capillary glucose measurements 
per 24 h
4·1 (0·9) 5·3 (1·6) 0·01
Data are mean (SD) or median (IQR), unless otherwise specified. AUCDay=area under the curve per 24-h period. *Primary 
endpoint.†Pre-breakfast n=21 for the closed-loop group, n=21 for the control group; pre-lunch n=21 (closed-loop) and 
n=20 (control); pre-evening meal n=21 (closed-loop) and n=22 (control); and pre-bed n=20 (closed-loop) and n=21 
(control). 
Table 2: Primary and secondary outcomes
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dextrose required in one episode (2·9 mmol/L; in the 
closed-loop group) because of a reduced level of 
consciousness and a blocked nasogastric tube. As per 
protocol, one patient in the closed-loop group received 
supplemental insulin in accordance with the instruction 
of the study team when sensor glucose was greater than 
18 mmol/L for more than 1 h.
No episodes of severe hypoglycaemia or significant 
hyperglycaemia with ketonaemia occurred in either 
group. Two severe adverse events (one cardiac arrest and 
one episode of acute respiratory failure resulting in 
death) occurred during the study (one case of acute 
respiratory failure in the closed-loop group and one case 
of cardiac arrest in the control group); neither was 
related to the study (table 4). No adverse events were 
related to study devices in either group (discontinuation 
due to intolerance of devices was not considered an 
adverse event). Device deficiencies occurred in five 
patients in the closed-loop group and two patients in the 
control group. The most common device deficiency was 
premature sensor failure (n=2 in the closed-loop group; 
n=2 in the control group). On each occasion the sensor 
was replaced within hours.
Discussion
In this randomised controlled trial, we have shown that 
fully closed-loop insulin delivery provided significantly 
better glycaemic control than did conventional sub- 
cutaneous insulin therapy in inpatients on enteral or 
parenteral nutrition (or both) in non-critical care. The 
proportion of time that the sensor glucose concentration 
was in the target range was significantly greater in the 
closed-loop group than in the control group, and the 
mean sensor glucose and SD were significantly lower in 
the closed-loop group. Improved glycaemic control was 
achieved without increasing the risk of hypoglycaemia 
and without an increase in total daily insulin dose.
Recommended glucose targets in non-critical care are 
not attainable by many health-care institutions with 
conventional insulin therapy.13,14 In this study, the benefits 
of fully closed-loop glycaemic control suggest that this 
technology has the potential to substantially improve 
management of hyperglycaemia in one of the most 
challenging inpatient populations. The advantage of 
fully closed-loop insulin delivery in this population is 
the instantaneous and continually adaptive glucose-
responsive modulation of insulin delivery, which can 
accommodate the glycaemic challenges associated with 
enteral and parenteral nutrition—such as unanticipated 
dislodgement of feeding tubes, temporary dis- continuation 
of nutrition, and cycling of enteral nutrition with oral 
intake. The closed-loop algorithm continually adapts to 
changing insulin needs during the day and between days, 
allowing increases in time spent in the target glucose 
range and lowering of mean glucose concentration without 
increasing time spent in hypoglycaemia. We used faster-
acting insulin aspart (Fiasp) because of its rapid onset and 
offset, to further improve the safety and efficacy of the 
closed-loop insulin delivery system. Conventional insulin 
therapy is less responsive to alterations in insulin 
requirements, and despite frequent blood glucose 
monitoring and regular adjustment of insulin doses, 
tighter glycaemic control with conventional therapy is 
associated with increased risk of hypoglycaemia and 
related adverse medical outcomes.15–17
Our study shows that overnight insulin requirements 
were higher in patients receiving nutritional support than 
in previous closed-loop inpatient studies,8,11 probably due 
to the timing and duration of the feed compared with 
patients with standard oral intake. This increased insulin 
requirement coupled with fear among health-care 
professionals of hypoglycaemia and associated adverse 
Figure 2: Sensor glucose concentration and insulin delivery profiles
(A) Sensor glucose concentration during closed-loop and control interventions from midnight to midnight 
(lines indicate median, shaded areas indicate IQRs). The glucose target range is 5·6–10·0 mmol/L. 
(B) Algorithm-directed insulin delivery during closed-loop intervention (line indicates median, shaded area 
indicates IQR).
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outcomes—especially overnight—might contribute to the 
prevalent hyperglycaemia in the control group. Indeed, 
time spent in hypoglycaemia was low in the control 
group, but was similar between groups.
Alternative approaches to improving glucose 
management in this population include use of variable-
rate intravenous insulin infusion; however, this method 
requires considerable staff workload with up to 2 h per 24 h 
period spent monitoring blood glucose and adjusting 
insulin infusion rates, precluding widespread use on 
general wards.18 Sub cutaneous insulin pump therapy 
adjusted with a titration algorithm every 4 h has shown 
some benefit over multiple daily insulin injections in 
patients receiving parenteral nutrition, reducing mean 
blood glucose and measures of glycaemic variability, but it 
does not provide feedback and adaptability and requires 
substantial input from health-care providers.19 The addition 
of insulin to parenteral nutrition is associated with variable 
availability of insulin and does not accommodate cycling of 
enteral nutrition with oral intake.20
Between-night sensor glucose variability was reduced 
with closed-loop therapy use compared with conventional 
therapy, but between-day sensor glucose variability did 
not differ significantly between groups. This result 
reflects the advantage of frequent modulation of insulin 
delivery based on sensor glucose, trading variability of 
insulin delivery with consistency in glucose concen-
tration. Previous studies have shown that higher 
glycaemic variability (measured by the SD and mean 
daily change in blood glucose) increases the risk of 
mortality in inpatients receiving parenteral nutrition.21
Identifying populations most likely to benefit from 
closed-loop glycaemic control is likely to be important for 
widespread adoption of this technology in the inpatient 
setting. Our findings expand on the results of a 
randomised trial that investigated use of a fully closed-
loop system in an unselected cohort of inpatients with 
hyperglycaemia.11 Despite potentially more challenging 
glucose management in our study due to the nutrition 
regimens prescribed, participants in the closed-loop 
group spent more than 16 h each day in the target glucose 
range, an additional 7·5 h compared with the control 
group.
Acceptability of closed-loop systems in the inpatient 
setting has been positive and the system has been 
designed to limit effects on mobility. Many inpatients 
require tubes and attachments for treatment of 
comorbidities other than diabetes. Future closed-loop 
systems will have a substantially smaller device burden. 
Implementation of closed-loop systems in the inpatient 
setting will require training for ward nursing staff. Set-
up, initialisation, and day-to-day management of the 
closed-loop system do not require specialist input. 
However, administration of intravenous insulin, which is 
currently undertaken by ward nursing staff, is more 
complex and has a higher risk of dosing error and health 
consequences. Future studies should assess to what 
extent the adoption of closed-loop technology adds to the 
complexity of staff duties. Surveillance for efficacy and 
safety will be possible with the remote monitoring 
capabilities of newer closed-loop platforms, allowing 
remote review of multiple patients on closed-loop 
systems across the hospital. Limitations to adoption 
include clinical inertia and time required to train health-
care professionals. Studies showing clinical benefit from 
closed-loop glycaemic control should help to overcome 
these barriers.
The strength of this study is the use of a novel approach 
to address the need for effective and safe management of 
hyperglycaemia in one of the most challenging inpatient 
populations. In the control group, glycaemic control was 
Closed-loop group 
(n=20)*
Control group 
(n=22)
p value
Overnight period (0000–0800 h)
Proportion of time spent at glucose concentration 
5·6–10·0mmol/L 
72·7% (17·2) 42·6% (28·7) 0·0002
Mean glucose concentration, mmol/L 8·3 (1·3) 10·3 (3·3) 0·013
SD of glucose concentration, mmol/L 1·8 (0·8) 2·9 (1·3) 0·002
Coefficient of glycaemic variability 20·8% (7·6) 28·6% (12·8) 0·021
Between night coefficient of glycaemic variability 17·7% (8·2) 26·0% (14·2) 0·026
AUCDay <3·5 mmol/L (mmol/l × min) 0·0 (0·0–0·0) 0·0 (0·0–4·5) 0·52
Insulin dose, units 17·9 (8·7–28·2) ·· ··
Daytime period (0800–0000 h)
Proportion of time spent at glucose concentration 
5·6–10·0 mmol/L 
66·5% (16·4) 34·4% (26·6) <0·0001 
Mean glucose concentration, mmol/L 8·6 (1·2) 11·8 (3·6) 0·0005
SD of glucose concentration, mmol/L 2·4 (0·8) 3·3 (1·3) 0·018
Coefficient of glycaemic variability 27·9% (6·5) 27·9% (9·3) 0·98
Between night coefficient of glycaemic variability 15·5% (5·3) 20·6% (11·5) 0·07
AUCDay <3·5 mmol/L (mmol/l × min) 1·7 (0·0–20·3) 0·0 (0·0–43·0) 0·91
Insulin dose, units 35·2 (17·8–57·2) ·· ··
Data are mean (SD) or median (IQR), unless otherwise specified. AUCDay=area under the curve per 24-h period. 
*One participant had no overnight data because they were in the study <12 h before transfer to intensive care unit. 
Table 3: Overnight (0000–0800 h) and daytime (0800–0000 h) outcomes
Closed-loop group 
(n=21)
Control group 
(n=22)
Number of severe hypoglycaemic events* 0 0
Number of significant hyperglycaemic events† 2 42
Number of participants with significant hyperglycaemic events† 2 (10%) 9 (41%)
Number of adverse events
Serious adverse events (not study related) 1 1
Non-serious adverse events (not study related) 5 4
Number of participants with adverse events 4 (19%) 4 (18%)
Number of device deficiencies 5 2
Number of participants with device deficiencies 5 (24%) 2 (9%)
Data are n or n (%). *Severe hypoglycaemia is defined as capillary glucose concentration of less than 2·2mmol/L or the 
patient requiring assistance from another member of health-care staff. †Significant hyperglycaemia is defined as 
capillary glucose concentration greater than 20 mmol/L. 
Table 4: Safety findings
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managed in accordance with local hospital guidelines, 
reflecting real-world practice. The two-country design 
allowed the safety and efficacy of fully closed-loop 
glycaemic control to be assessed across different health-
care systems, supporting generalisability. The closed-
loop system used commercially available components, 
allowing ease of use in different health-care settings and 
potentially allowing accelerated adoption of the system 
for future widespread clinical use.
The study design was pragmatic because of the 
heterogeneity of the study population, allowing individ-
ualised treatment intensification on a patient-by-patient 
basis in the control group and reflecting usual clinical 
practice in the two centres. Insulin regimens and the 
frequency of glucose monitoring varied within the 
control group. Both centres had an inpatient diabetes 
service and patients in the control group referred to the 
diabetes team had capillary glucose measurements 
reviewed every 1–2 days depending on patient complexity, 
with insulin doses adjusted as required, whereas patients 
not referred to the inpatient diabetes team had capillary 
glucose monitoring and insulin dose adjustment done by 
the clinical team. The target glucose range varies for 
hospital inpatients in non-critical care. Tight glycaemic 
control is associated with increased mortality in the 
intensive care setting because of an increased risk of 
hypoglycaemia.22 However, the target glucose concen-
tration range of 5·6–10·0 mmol/L used in our study is 
more appropriate on general wards, where the nursing 
staff-to-patient ratio is lower, and high workloads often 
prevent more frequent glucose monitoring. 
This study has limitations, including the small number 
of patients. Sensor glucose data availability was higher in 
the closed-loop group than in the control group. In the 
closed-loop group, the research team were notified of any 
loss of connectivity between sensor and receiver device 
by an alarm, whereas the glucose sensor was masked in 
the control group and such connectivity interruptions 
were not detected, leading to reduced sensor glucose 
data.
In conclusion, we have shown that fully closed-loop 
insulin delivery in inpatients receiving parenteral or 
enteral nutrition (or both) is safe and significantly 
improves glycaemic control without increasing the risk 
of hypoglycaemia compared with conventional insulin 
therapy in non-critical care. Further studies are required 
to assess whether closed-loop glycaemic control can 
translate into improved clinical outcomes and is cost-
effective in particular patient cohorts to support wide-
spread adoption by health-care systems.
Contributors
RH coordinated the study. RH, CKB, LB, SH, MEW, MLE, APC, 
and CS co-designed the study. CKB, LB, and SH were responsible for 
screening and enrolment of participants, arranged informed consent 
from the participants, and provided patient care. CKB, LB, and RH wrote 
the report. CKB, LB, MEW, and RH contributed to data analysis, 
including statistical analyses. RH designed and implemented the 
glucose controller. RH, CKB, LB, FM, SH, DH, AV, MMW, MEW, MLE, 
APC, and CS contributed to the interpretation of the results. All authors 
critically reviewed the report.
Declaration of interests
SH serves as a consultant for Novo Nordisk and for the ONSET group 
and reports having received speaker or training honoraria from 
Medtronic. MLE reports having received speaker honoraria from 
Abbott Diabetes Care, Novo Nordisk, and Animas, and having served on 
advisory panels for Novo Nordisk, Abbott Diabetes Care, Medtronic, 
Roche, and Cellnovo. RH reports having received speaker honoraria 
from Eli Lilly and Novo Nordisk, having served on advisory panels for 
Eli Lilly and Novo Nordisk, and having received licence fees from 
BBraun and Medtronic. RH and MEW report patents and patent 
applications related to closed-loop insulin therapy. All other authors 
declare no competing interests.
Data sharing
No additional data are available.
Acknowledgments
The study was funded by Diabetes UK (#14/0004878), the Swiss National 
Science Foundation (P1BEP3_165297), the National Institute for Health 
Research Cambridge Biomedical Research Centre, the Wellcome Trust 
(Strategic Award 100574/Z/12/Z), and the European Foundation for the 
Study of Diabetes. Additional support for artificial pancreas research has 
been provided by JDFR. Abbott Diabetes Care supplied discounted 
continuous glucose monitoring devices, sensors, and details of 
communication protocols to facilitate real-time connectivity (the 
company had no role in the conduct of the study). LB received financial 
support from the University Hospital Bern, University of Bern, and the 
Swiss Diabetes Foundation. We are grateful to study volunteers for their 
participation. We acknowledge support by the ward staff at 
Addenbrooke’s Hospital, Cambridge University Hospitals NHS 
Foundation Trust, Cambridge, UK and Inselspital, Bern University 
Hospital, Bern, Switzerland. Josephine Hayes (University of Cambridge) 
provided administrative support. Michèle Monnard (University Hospital 
Bern) supported data management in Bern. Jasdip Mangat supported 
development and validation of the closed-loop system. 
References
1 Correia MI, Waitzberg DL. The impact of malnutrition on 
morbidity, mortality, length of hospital stay and costs 
evaluated through a multivariate model analysis. Clin Nutr 2003; 
22: 235–39.
2 Pleva M, Mirtallo JM, Steinberg SM. Hyperglycemic events in 
non-intensive care unit patients receiving parenteral nutrition. 
Nutr Clin Pract 2009; 24: 626–34.
3 Pancorbo-Hidalgo PL, Garcia-Fernandez FP, Ramirez-Perez C. 
Complications associated with enteral nutrition by nasogastric tube 
in an internal medicine unit. J Clin Nurs 2001; 10: 482–90.
4 Pasquel FJ, Spiegelman R, McCauley M, et al. Hyperglycemia 
during total parenteral nutrition. Diabetes Care 2010; 33: 739–41.
5 Cheung NW, Napier B, Zaccaria C, Fletcher JP. Hyperglycemia is 
associated with adverse outcomes in patients receiving total 
parenteral nutrition. Diabetes Care 2005; 28: 2367–71.
6 Gonzalez Infantino CA, Gonzalez CD, Sanchez R, Presner N. 
Hyperglycemia and hypoalbuminemia as prognostic mortality 
factors in patients with enteral feeding. Nutrition 2013; 29: 497–501.
7 Olveira G, Tapia MJ, Ocón J, et al. Parenteral nutrition-associated 
hyperglycemia in non-critically ill inpatients increases the risk of 
in-hospital mortality (multicenter study). Diabetes Care 2013; 
36: 1061–66.
8 Thabit H, Hartnell S, Allen JM, et al. Closed-loop insulin delivery in 
inpatients with type 2 diabetes: a randomised, parallel-group trial. 
Lancet Diabetes Endocrinol 2017; 5: 117–24.
9 Leelarathna L, English SW, Thabit H, et al. Feasibility of fully 
automated closed-loop glucose control using continuous 
subcutaneous glucose measurements in critical illness: 
a randomized controlled trial. Crit Care 2013; 17: R159.
10 Umpierrez GE, Hellman R, Korytkowski MT, et al. Management of 
hyperglycemia in hospitalized patients in non-critical care setting: 
an endocrine society clinical practice guideline. 
J Clin Endocrinol Metab 2012; 97: 16–38.
11 Bally L, Thabit H, Hartnell S, et al. Closed-loop insulin delivery for 
glycemic control in noncritical care. N Engl J Med 2018; 379: 547–56.
Articles
www.thelancet.com/diabetes-endocrinology   Vol 7   May 2019 377
12 Evans S, Day S, Royston P. Minim: minimisation program for 
allocating patients to treatments in clinical trials. https://www-
users.york.ac.uk/~mb55/guide/minim.htm (accessed Feb 22, 2019).
13 Health and Social Care Information Centre (HSCIC). National 
Diabetes Inpatient Audit (NaDIA) 2017—National Report. Leeds: 
NHS Digital, 2017.
14 Swanson CM, Potter DJ, Kongable GL, Cook CB. Update on 
inpatient glycemic control in hospitals in the United States. 
Endocr Pract 2011; 17: 853–61.
15 Christensen MB, Gotfredsen A, Norgaard K. Efficacy of basal-bolus 
insulin regimens in the inpatient management of non-critically ill 
patients with type 2 diabetes: a systematic review and meta-analysis. 
Diabetes Metab Res Rev 2017; 33: e2885.
16 Murad MH, Coburn JA, Coto-Yglesias F, et al. Glycemic control 
in non-critically ill hospitalized patients: a systematic review and 
meta-analysis. J Clin Endocrinol Metab 2012; 97: 49–58.
17 Nirantharakumar K, Marshall T, Kennedy A, Narendran P, 
Hemming K, Coleman JJ. Hypoglycaemia is associated with 
increased length of stay and mortality in people with diabetes 
who are hospitalized. Diabet Med 2012; 29: e445–48.
18 Aragon D. Evaluation of nursing work effort and perceptions about 
blood glucose testing in tight glycemic control. Am J Crit Care 2006; 
15: 370–77.
19 Li FF, Zhang WL, Liu BL, et al. Management of glycemic variation 
in diabetic patients receiving parenteral nutrition by continuous 
subcutaneous insulin infusion (CSII) therapy. Sci Rep 2018; 8: 5888.
20 McCulloch A, Bansiya V, Woodward JM. Addition of insulin to 
parenteral nutrition for control of hyperglycemia. 
JPEN J Parenter Enteral Nutr 2018; 42: 846–54.
21 Farrokhi F, Chandra P, Smiley D, et al. Glucose variability is an 
independent predictor of mortality in hospitalized patients treated 
with total parenteral nutrition. Endocr Pract 2014; 20: 41–45.
22 NICE-SUGAR Study Investigators. Intensive versus conventional 
glucose control in critically ill patients. N Engl J Med 2009; 
360: 1283–97.
